Th17 and cancer: Friends or foes?

Blood

Volumn 112, Issue 2, 2008, Pages 214-

  Bronte, Vincenzo ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 23; MELANOMA ANTIGEN; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POLARITY; MELANOMA; MYELOMA; NONHUMAN; NOTE; PRIORITY JOURNAL; TH17 CELL;

EID: 55149114870     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-149260     Document Type: Note

References (5)

1. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer. a clinical path to eftective cancer immunotherapy. Nat Rev Cancer. 2008;8:299-308.
2. Reiner SL. Development in motion: helper T cells at work. Cell. 2007;129:33-36.
3. Langowski JL, Zhang X, Wul, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442:46465.
4. Hu J, Yuan X, Bclladonna ML, et al. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells Cancer Res. 2006;66: 8887-8896.
5. Kryczek I, Wei S, Zou L, et al. Cutting edge: Th 17 and regulatory T cell dynamics and the rgulation by IL-2 in the tumor microenvironment. J Immunol. 2007;178:6730-6733.